<DOC>
	<DOC>NCT00099268</DOC>
	<brief_summary>The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in a decrease in the risk of the development of motor complications for patients with Parkinson's disease.</brief_summary>
	<brief_title>Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa, levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>Clinical diagnosis of idiopathic Parkinson's disease Diagnosis of Parkinson's disease for no more than 5 years History, signs, or symptoms of atypical or secondary parkinsonism Presence at baseline of drugrelated wearingoff symptoms, dyskinesia or other motor complications Levodopa exposure of more than 30 days or anytime within 8 weeks prior to visit 1 Other inclusion/exclusion criteria applied to this study.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Parkinson's disease, levodopa therapy, dyskinesia</keyword>
</DOC>